Skip to main content

Posters

November 22, 2019
BACKGROUND: In the 12-week ARM-TD and AIM-TD studies of patients with tardive dyskinesia (TD), the percentage of patients achieving ≥50% and ≥70% responses (i.e. reductions from baseline in Abnormal Involuntary Movement Scale (AIMS) scores) was higher in the deutetrabenazine-treated group compared…
November 22, 2019
Depression occurs in ~50% of Parkinson’s disease (PD) patients, increases in severity as the disease progresses, and is associated with increased morbidity. We are assessing use of pimavanserin (PIM) for treatment of depression in adults with PD. A Phase-2, 8-week, open-label, single-arm safety and…
November 22, 2019
BACKGROUND: Many MDD patients fail to achieve remission. Current literature focuses on one major depressive episode (MDE); treatment over multiple MDEs has not been extensively explored. OBJECTIVE: To characterize treatment patterns within and across multiple MDEs.
November 22, 2019
BACKGROUND: Patients with major depressive disorder (MDD) who experience clinical events of interest (EOIs) such as suicide attempt/ideation and hospitalization may incur greater costs. The objective of this study was to estimate all-cause healthcare costs (per patient per year [PPPY]) among MDD…
November 22, 2019
Introduction: ASPIRE-1 is one of two global phase-3 studies in the registration program to evaluate efficacy and safety of esketamine nasal spray (ESK) vs placebo, with comprehensive standard-of-care (SoC), in patients with major depressive disorder (MDD) at imminent risk for suicide.
November 22, 2019
Sexual dysfunction occurs in 40%-60% of patients with major depressive disorder (MDD), due to either the illness itself and/or the effects of antidepressant treatment. The phase-2 CLARITY trial recently demonstrated the efficacy of adjunctive pimavanserin (PIM) for MDD when added to ongoing…
November 22, 2019
NeuroStar® Advanced Therapy System is an effective acute treatment for patients with Major Depressive Disorder (MDD). To further understand the efficacy of the NeuroStar in a clinical setting, Neuronetics has established a patient treatment and Outcomes Registry to collect and analyze the efficacy…
November 22, 2019
Introduction: Efficacy and safety of esketamine (ESK) nasal spray were evaluated in ASPIRE-2 (NCT03097133), one of two phase-3 studies in the first global registration program in an understudied population of patients with major depressive disorder (MDD) at imminent risk for suicide.
November 22, 2019
Background: Outcomes for treating depression remain suboptimal, despite increasing medication options. Early work has shown that personalized genomics testing can improve treatment outcomes in many fields of medicine. However, no prior work has investigated the efficacy of pharmacogenetic testing…
November 22, 2019
BACKGROUND: Incremental economic burden of treatment resistant depression (TRD) in patients with behavioral comorbidities is largely unknown.
Back to Top